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Background: Survival rates following a diagnosis of cancer vary between countries. The International Cancer
Benchmarking Partnership (ICBP), a collaboration between six countries with primary care led health services, was
set up in 2009 to investigate the causes of these differences. Module 3 of this collaboration hypothesised that an
association exists between the readiness of primary care physicians (PCP) to investigate for cancer – the ‘threshold’
risk level at which they investigate or refer to a specialist for consideration of possible cancer – and survival for that
cancer (lung, colorectal and ovarian). We describe the development of an international survey instrument to test
this hypothesis.
Methods: The work was led by an academic steering group in England. They agreed that an online survey was the
most pragmatic way of identifying differences between the jurisdictions. Research questions were identified
through clinical experience and expert knowledge of the relevant literature.
A survey comprising a set of direct questions and five clinical scenarios was developed to investigate the
hypothesis. The survey content was discussed and refined concurrently and repeatedly with international partners.
The survey was validated using an iterative process in England. Following validation the survey was adapted to be
relevant to the health systems operating in other jurisdictions and translated into Danish, Norwegian and Swedish,
and into Canadian and Australian English.
Results: This work has produced a survey with face, content and cross cultural validity that will be circulated in all
six countries. It could also form a benchmark for similar surveys in countries with similar health care systems.
Conclusions: The vignettes could also be used as educational resources. This study is likely to impact on healthcare
policy and practice in participating countries.
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There are acknowledged differences in cancer survival
rates between countries with similar, primary health
care led health systems [1]. The International Cancer
Benchmarking Partnership (ICBP) was established with
the aims of producing up-to-date survival estimates for
selected cancers (breast, colorectal, lung, ovary), estab-
lishing whether these differences have changed over time
and particularly to investigate possible causes of survival
deficits identified [2]. It comprises five work streams,
one of which (Module 3) is focused on primary care as-
pects of cancer diagnosis. Specifically, this aspect relates
to the period between the patient’s first presentation to a
primary care practitioner (PCP) with a symptom of pos-
sible oncological significance up to the time that a refer-
ral is made to secondary care for further diagnostic
investigation or for treatment, when the diagnosis of
cancer is made in primary care.
There is increasing evidence that the time from first
presentation of cancer to diagnosis is associated with
prognosis [3-5]. The aim of Module 3 was to identify dif-
ferences in primary care systems, structure or clinical
practice that might contribute to known differences in
cancer outcomes between ICBP jurisdictions. Specifically
this related to factors that might influence delay in diag-
nosis or referral within primary care [6]. Such factors
can be: 1) structural, such as access to investigations, ac-
cess to specialist advice, 2) organisational, such as degree
of gatekeeping [7] and safety netting practices, and 3)
knowledge and skills, such as the awareness of cancer
symptoms and diagnostic skills among PCP.
In order to undertake such a study, we needed a valid
and reliable measure of the differences in awareness,
skills, structure and organisation between different pri-
mary care settings. The aim of this paper is to present
the development of this measurement tool and the
challenges that had to be addressed in the design and
conduct of a survey of ICBP jurisdictions. The eleven
jurisdictions, located in six countries, were England,
Northern Ireland, Wales, Denmark, Norway, Sweden,
British Columbia, Manitoba, Ontario, New South Wales
and Victoria. Each jurisdiction contributed to the costs
of the project and necessary ethical approvals.
Methods
Conceptualisation
A group of primary care practitioners with expertise of
cancer diagnosis, drawing on input from a review of lit-
erature, clinical experience and advice from a group of
three international experts in the field, identified features
and aspects of primary care systems, organisation and
clinical practice which could contribute to international
differences in the diagnosis of cancer [8-15]. From this a
set of hypotheses was generated for testing (Figure 1).Features of primary care practice which were hypothe-
sised as being influential included health system factors,
diagnostic factors and referral factors as well as factors
related to PCP behaviours, attitudes, skills, knowledge,
practice administration and incentives. Initially, screen-
ing was also included but was then removed as the pri-
mary aim was in explaining differences in symptomatic
diagnosis. The process was iterative, starting with all fac-
tors that could be relevant and then reducing these
based on perceived importance, relevance to all jurisdic-
tions, and feasibility for testing in a survey format. Deci-
sions were made on a consensus basis until there was
agreement on the form, structure and content of the sur-
vey to fully investigate the hypothesis. Teleconferences
were scheduled at regular intervals and active email
communication conducted to facilitate decision making
at all stages of the study.
The features that were hypothesised to be important
in understanding and evaluating differences between
countries were grouped into two main categories: gen-
eral structural and cultural factors; and specific clinical,
educational and organisational aspects. We chose to
focus on the features related to the individual PCP and
their activity in relation to cancer diagnosis. An inter-
national collaboration ethics approval was sought as re-
quired in each jurisdiction (see Figure 1).
To capture the differences in the generic aspects of
health care systems, the ICBP Programme Board
commissioned a comparative analysis of health care sys-
tems to contextualise the results of this study. This ‘sys-
tem mapping’ exercise represents a comparison of the
health care systems found in each jurisdiction relating to
cancer diagnosis, is reported elsewhere (Brown S, Rubin
G, Castelli M, Hunter DJ, Erskine J, Vedsted P, Foot C:
How might health care systems influence speed of can-
cer diagnosis: a narrative review, in preparation).Key hypotheses of causes of delays to cancer diagnosis in
primary care
To ensure content validity was present for all jurisdic-
tions, all features were discussed iteratively. Recognising
that long surveys affect response and completion rates,
consensus was reached between the collaborators on the
features considered to be the most important (Figure 1).Choice of data collection method
A number of methodologies were considered including a
questionnaire survey, system mapping, primary care
notes review, simulated cases, qualitative interviews or
focus groups with PCPs. We opted for survey method-
ology delivered electronically, as the most easily repro-
ducible in several countries and languages, the easiest in
which to maintain consistency between countries and its
Figure 1 Systematic, organisational and clinical factors within primary care which could contribute to international differences in
cancer diagnosis.
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number of PCPs.
Operationalisation and development of survey
The survey was developed in two parts. The first part
consisted of five clinical vignettes to capture the aspects
of recognition of ‘low-risk but not no-risk’ symptoms,
delay in instigating investigations and reluctance to con-
sider an alternative diagnosis. Vignettes are recognised
to produce a better assessment of quality of care com-
pared to record audit and they are faster to perform and
more economical [16]. Vignettes also predict physician
performance as judged against consultations with trained
actors and can be a good measure of process of care
[17]. They have also been validated in electronic form
and used to measure care across different health systems
in California [18].
The vignettes were based on common clinical presen-
tations of possible lung (two vignettes), colorectal (two
vignettes) and ovarian (one vignette) cancers. They were
evidence-based, using primary care evidence on symp-
toms/sign and positive predictive values [19-22]. Breastcancer was omitted as we considered it very likely all
women with a breast lump would be investigated, and
there is very little primary care evidence to support in-
vestigation/non-investigation of other breast symptoms.
Each vignette was presented in two or three “phases”,
with the second and third phase of each vignette represent-
ing a further presentation of the patient with additional
symptoms or worsening severity of initial symptoms. Re-
spondents were asked questions about management of the
cases, using a drop-down menu for responses. The vignette
ended if the respondent decided to refer the patient to hos-
pital or undertake a test themselves that would confirm a
diagnosis of cancer if present (chest xray or lung CT for
lung vignettes, colonoscopy or abdominal CT for colorectal
vignettes, abdominal CT or abdominal or trans-vaginal
ultrasound for the ovarian vignette). We labelled these
‘near-definitive’ tests, while accepting each has a (small)
false-negative and false-positive rate. Other common pri-
mary care tests, such as haemoglobin or tumour markers
have considerably less predictive accuracy, so if a respond-
ent chose to perform one of these, the vignette continued.
At the end of the vignette the respondent was given a
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come in three vignettes (2, 4 and 5) was cancer. In two
vignettes (1 and 3) the final diagnosis was not cancer
(i.e. bronchiectasis, symptoms cleared up). This was
done to reduce the bias inherent in assessing clinical
performance when respondents were aware the survey
related to cancer diagnosis. The assessment was based
on the management of each vignette and the final out-
come was not relevant to this.
The second part of the survey consisted of direct ques-
tions addressing aspects of the responder’s local health
care system and their own attitudes and education.
Simple demographic data relating to gender, type of
PCP, time since qualification, location of training and
rurality of practice were also identified.
Collaborators in all jurisdictions agreed to develop a
core survey relevant to all, but to allow individual juris-
dictions to add a small number of additional locally rele-
vant questions at the end of the survey. These additional
questions were subject to approval based on the overall
length of the survey being acceptable to the central re-
search team.
Overseeing the instrument development
At every stage the development of the instrument was
discussed with the ICBP Programme Board and the
Module 3 leads from each participating jurisdiction.
The challenges of ensuring participation in teleconfer-
ences across disparate time zones was successfully
addressed by holding teleconferences with identical
agendas at two different times in the same day, with
the chair and programme management team present at
both to provide continuity.
Validation
At every stage, the survey was discussed with each juris-
diction to confirm that features being assessed were rele-
vant to the hypotheses, whilst remaining locally cogent.
During this process, some questions were omitted due
to lack of international applicability. These included the
relevance and use of guidelines which varied between
jurisdictions, issues of differential care to remote com-
munities (relevant to Canada, Australia and Norway),
variations in care between publicly and privately insured
patients, and questions related to screening of asymp-
tomatic patients. Each of these factors was seen to
have particular local pertinence, but less international
relevance. These were topics taken up by some juris-
dictions that asked additional (non-core) questions in
their local survey. Thus, content validity of the aspects
was ensured during the conceptualisation.
The face validity of the final items was tested twice.
The initial survey was piloted by four English academic
PCPs who were asked to complete a paper-basedversion of the survey and give written and verbal feed-
back on the relevance of items, whether the items cov-
ered the area of interest and whether they would be
able to interpret results from the answers. They were
also asked about their understanding of the questions.
Amendments were made in the light of their feedback
to develop a second draft.
The second draft was tested out on seven English
PCPs of varying age, gender and background. Six were
seen face to face and the seventh provided written feedback.
The PCPs were asked to complete a prototype electronic
version of the survey in the presence of the researcher, who
then used a cognitive interviewing technique to ascertain
the relevance of the survey and its content, including un-
derstanding of the meaning of the questions involved. The
PCPs considered instructions to be appropriate, the content
was relevant and the vignettes represented clinical cases
that they could recognise from their clinical practice [16].
They were clear that the purpose of the vignettes was not a
‘test’ of their practice, but to identify how they would man-
age a patient’s symptoms. Suggestions were made to clarify
the meaning of some items.
Feasibility was tested on both of these occasions with all
PCPs reporting that the time to complete the survey was
reasonable; all completed the survey within 20 minutes.
Results
Testing consistency
In the vignettes the respondents were asked how they
would manage each case, including which investigations
they would undertake in primary care. Respondents were
asked to choose only tests that they had direct access to
(tests that could be ordered by the GP without reference
to a specialist doctor) in their own practice. In the direct
question section, respondents were also asked which tests
were available by direct access in their jurisdiction. As a
measure of consistency, we measured how many respon-
dents ordered tests in the vignettes that were not available
to them through direct access, according to their response
to the question on this point. This cross-validation exer-
cise was performed on the first jurisdiction to complete
the survey (Denmark). We identified and assessed the use
of those tests where at least 80% of respondents did not
have direct access to the tests: CT/MRI of lung for
vignettes one and two, CT abdomen for vignettes three,
four and five and colonoscopy for vignettes three and four.
The percentages of these Danish respondents who ordered
these tests despite stating no access were low: vignette one
= 9%; vignette two = 4.2%; vignette three, CT abdomen =
0%, colonoscopy = 0%; vignette four, CT abdomen = 2.9%,
colonoscopy = 0%; vignette five, CT abdomen = 5.3%.
We did not determine test-retest reliability because we
predicted that answers would differ over time. This would
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the outcome of each vignette at the end of the survey.
Translation and adaptation
The final English version of the survey was adapted in
the other English-speaking countries outside the UK.
For the Canadian and Australian jurisdictions, there was
an adaptation of certain specific terms to improve sense
in these jurisdictions (such as ‘office’ or ‘clinic’ instead of
‘practice’). Together with the collaborators in Canada it
was agreed not to make a translation into Canadian
French and with collaborators in Wales not to make a
translation in Welsh.
The final validated UK English version of the survey
was translated into Danish, Norwegian and Swedish,
following methods already described [23]. To take ad-
vantage of the commonalities between the Scandinavian
languages, the survey was first translated into Danish.
The translation into Danish followed a standardised
process [23]. Translations were done by two native Da-
nish speakers who spoke good English (one profession-
ally in English medical language and one an English
correspondent). The translation was then checked by
two Danish PCPs and any problems discussed with the
translators at an expert meeting. Then there was a back-
translation into English made by two English native
speakers who also spoke Danish fluently. Both were familiar
with medical terminology. The back-translation was com-
pared and discussed and semantic differences with the ori-
ginal version were discussed at a second expert meeting.
We aimed for conceptual and cultural equivalence rather
than a verbatim translation. Items were culturally adapted
to reflect the Danish healthcare systems. Discussion be-
tween the central team and Danish collaborators was then
undertaken to check equivalence of linguistic, cultural and
professional meaning with the UK English version.
The final Danish version was then pilot tested among
four PCPs before being translated into Swedish and Norwe-
gian. These translations were made by a single translation
into Swedish and Norwegian, respectively. These versions
were not back-translated. The final Norwegian and Swedish
versions were culturally and structurally adapted. The
Swedish version was also tested on 20 PCPs and registrars.
Pilot testing of the final version
The survey was converted into an electronic version by
a commercial company (Sigmer Technologies Limited).
The electronic version was then tested by 16 PCPs in
the UK. No issues were identified concerning how the
electronic version of the survey worked. However, the
time taken to complete all five vignettes was considered
to be too long and the central team decided to ask each
respondent to answer only two vignettes each. These vi-
gnettes were assigned randomly, with each referring to adifferent cancer, with either a positive cancer diagnosis
followed by a negative vignette or vice versa. Respondents
knew this was a cancer related survey, so the choice and
outcome of vignettes was randomized to minimise bias.Sample selection
Each jurisdiction decided on a method of sampling and
approach to potential participants (regular post or
email), dependant on local conditions and the avail-
ability of databases with PCP contact details. Partici-
pants were PCPs in regular day time primary care,
locums or those working in ‘out-of-hours’ services.
Retired PCPs and those in training were not eligible,
and other primary care providers such as nurse practi-
tioners were not included.Sample size
Each jurisdiction was expected to recruit at least 200
respondents. A sample size of 200 has a 95% confidence
interval (CI) of 43-57% for an equally distributed response
(50% respond ‘yes’), and a CI of 15-26% for a response
where 20% of respondents say ‘yes’.Analysis plan
The answers to direct questions will be presented as
simple descriptive statistics. This will enable comparison
between jurisdictions of several stages of the process
from presentation of cancer symptoms to diagnosis in
primary care or referral. This includes length of consul-
tations, safety-netting practices (processes to ensure ap-
propriate patient follow-up), availability and wait for
tests and test results, availability of advice and speed of
referral to first appointment.
The main outcome of interest in the vignettes will be
the proportion of respondents in each jurisdiction who
‘completed’ the vignette (i.e. made a referral or undertook
a definitive diagnostic test) at each stage compared to the
one-year survival and five-year [conditional on one year]
survival for that cancer in a given jurisdiction [1,24]. Both
of these survival outcomes are affected by factors in the
period before referral to hospital. The conditional 5 year
survival (i.e. 5 year survival conditional on surviving at
least 1 year) minimises the impact of factors that primarily
affect survival in the first year after diagnosis, such as de-
lays in diagnosis and aggressiveness of the tumour. Re-
gression analyses will seek associations between other
factors investigated in the survey and survival rates.The final survey
Copies of the survey are available upon request from
the ICBP programme management team at icbp@
cancer.org.uk.
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This paper describes the development of a survey to assess
the differences in primary care as it relates to cancer diag-
nosis amongst 11 jurisdictions (England, Northern Ireland,
Wales, Denmark, Norway, Sweden, British Columbia,
Manitoba, Ontario, New South Wales and Victoria) that
make up part of the ICBP. The purpose of the survey is to
identify and understand differences in primary care systems
and in the clinical practice of PCPs that might explain the
differences in cancer outcomes between these jurisdictions.
The survey was tested extensively before completion, in-
cluding checks to ensure cross-cultural validity.
Other surveys have used similar methodology, espe-
cially relating to the use of vignettes and this method
has good correlation with clinical practice [18]. There
are no similar surveys investigating the diagnosis of can-
cer across a large number of jurisdictions. The survey is
relevant to clinical practice in countries with a primary
care led health service and contains clinical situations
that are familiar to PCPs. The electronic nature of the
survey makes it possible to use vignettes with multiple
options. It is easily accessible and easy to conduct and it
will provide strong comparative data as a result. Its use
would be restricted in countries with limited internet ac-
cess for PCPs.
Iterative testing of the survey was undertaken, both in
England where the survey was developed but also in
some other jurisdictions to ensure face validity, content
validity and cross cultural validity. Extensive piloting
among all jurisdictions was limited by the need to de-
velop the survey at the same time as jurisdictions were
being recruited and adapting the survey for local use.
More extensive pilot testing was also limited by con-
straints of time and resources. Reliability testing was
consequently difficult in the pilot stage due to small
numbers of respondents in the pilot stages, but testing
of consistency in the early stage of the actual survey
showed a high level of consistency in the vignettes with
the exception of the use of CT lung scans in the lung
cancer vignettes; 9% of respondents ordering a lung CT
to investigate the cases had stated that they did not have
access to this test. However, even in these vignettes
consistency scores were considered acceptable.
Restricting the survey to only two of five possible vi-
gnettes might affect validity of results by reducing the
sample size for each vignette. However, this was felt ne-
cessary to ensure survey completion time was reasonable
and to enable exploration of other issues not amenable
to the use of vignettes, including structural and organ-
isational factors.
The survey will have future value in providing a bench-
mark against which other studies could be measured and in
providing a ‘template’ that could be adjusted to local circum-
stances for similar studies to be undertaken in other settings.Conclusions
We have developed and validated a survey instrument
that investigates the diagnosis of cancer by primary care
physicians. We intend to use the instrument to compare
current practice between six countries whose health ser-
vices are led by primary care. Other countries with simi-
lar health systems could use this study as a benchmark
and the survey could be repeated to identify changes
with time. The vignette part of the survey could also be
used as an educational tool.
We anticipate that the findings from ICBP Module 3
will have an impact on healthcare policy and practice in
the participating jurisdictions and begin to indicate pri-
mary care factors that could impact on survival differ-
ences between participating jurisdictions.
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